A recent meta-analysis of 16 randomized controlled trials involving patients with HF, with and without T2D, showed that SGLT2 inhibition was associated with a modest but significant reduction in systolic BP (1.68 mmHg), but not in diastolic BP (1.06 mmHg). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.